Credit: Getty Images. Rezlidhia is a small molecule inhibitor of mutated IDH1. Rezlidhia ™ (olutasidenib) is now available for the treatment of adults with relapsed or refractory acute myeloid ...

Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia; Rigel Pharmaceuticals, ...

Panelists discuss how IDH inhibitors, particularly ivosidenib combined with azacitidine, represent potentially the greatest advance in AML treatment due to significant overall survival improvements, ...

The FDA has granted fast track designation to zotiraciclib (TG02), an oral central nervous sytem-penetrant multikinase inhibitor, for treatment of patients with recurrent high-grade gliomas (rHGG) ...

Impact of MGMT promoter methylation in glioblastoma of the elderly. Background: Recent studies have shown that IDH1 mutations occur frequently in WHO grade 2 and 3 gliomas. However, their prognostic ...

Association of matrix metalloproteinase 2 (MMP2) baseline plasma level to objective response (OR), progression free survival (PFS), and overall survival (OS) and changes under treatment in patients ...

Brain cancer is difficult to treat when it starts growing, and a prevalent type, known as a glioma, has a poor five-year survival rate. In a new study, researchers report on a new surgical platform ...

Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with relapsed or ...